Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance Advances Respiratory Program via Glaxo Partnership

This article was originally published in Start Up

Executive Summary

The goal of the deal between Glaxo and Theravance is to pool programs in order to develop a best-in-class long-acting beta agonist. That Glaxo is contributing its most advanced compounds to the program and has agreed to pay royalties even on LABAs it may develop separately validates Theravance's technology. But it also shows how Glaxo is weighing the value of external vs. internal R&D.

You may also be interested in...



GSK's Risk-Sharing Deals to Compete with In-House R&D

Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.

GSK's Risk-Sharing Deals to Compete with In-House R&D

Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.

Theravance/Astellas: Quality Deal but without the Brand Name

Branding works--in packaged goods and among investors. That's why, rather than taking Theravance's rich marketing deal with the Japanese company Astellas for the antibiotic telavancin -- rich in comparison to the best licensing deals signed in the segment -- as a net positive for the company, shareholders seemed disappointed.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel